Korro Bio Names KRRO-111 as Development Candidate for Alpha-1 Antitrypsin Deficiency with Strong Preclinical Data

summarizeSummary

Korro Bio announced KRRO-111 as a new development candidate for Alpha-1 Antitrypsin Deficiency, presenting strong preclinical data demonstrating high RNA editing efficiency and functional protein restoration.

check_boxKey Events

• New Development Candidate KRRO-111

  Korro Bio selected KRRO-111 for Alpha-1 Antitrypsin Deficiency (AATD), expanding its pipeline of therapeutic programs.

• Strong Preclinical Efficacy

  KRRO-111 demonstrated over 90% editing of the SERPINA1 transcript and approximately 90% repaired functional AAT protein in mouse models, along with near elimination of pathogenic Z-protein.

• Platform Validation

  The results validate Korro Bio's OPERA® platform, showing potential for best-in-class genetic medicines by achieving high levels of specific protein correction at the RNA level.

• Reiterated Financial Runway

  The company confirmed it is well-capitalized with a cash runway into the second half of 2028, enabling the advancement of KRRO-111 and KRRO-121 programs.

auto_awesomeAnalysis

Korro Bio has advanced KRRO-111 into its development pipeline for Alpha-1 Antitrypsin Deficiency (AATD), backed by compelling preclinical results. The data shows over 90% RNA editing and restoration of functional protein, along with a near elimination of pathogenic Z-protein in mouse models. This represents a significant step in validating the company's OPERA platform and expanding its therapeutic pipeline, building on recent financing that extended its cash runway.